Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of d-MPH in the Treatment of Fatigue and Neurobehavioral Impairment Related to Chemotherapy in Adult Cancer Patients

Celgene Corporation21 个研究点分布在 1 个国家目标入组 160 人开始时间: 2002年6月1日最近更新: 2005年6月24日

适应症

试验速览

To evaluate the efficacy of dexmethylphenidate (d-MPH) in the treatment of chemotherapy-related fatigue in adult cancer subjects.

•Diagnosis of cancer, excluding primary or metastatic brain tumors.
•Treated with a minimum of four cycles of a cytotoxic chemotherapy, the last chemotherapy treatment must have been completed at least 2 months prior to study entry.
•Physical/neurological examination consistent with the absence of a focal neurological deficit
•Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test. In addition, sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner).
•Subjects must be able to adhere to the protocol requirements.
•Subjects must understand and voluntarily sign an informed consent document.
•Subjects must be a native English speaker or fluent in English, and have at least an eighth grade education.

发起方

申办方类型

Industry

Loading locations...